Last week our CEO Ben Shepherd had the opportunity to spend a few days in Washington D.C. at the Kidney Innovation Conference with KidneyX, KidneyCure, and the Kidney Health Initiative. It was an incredible group of patients, their advocates, innovators, policy makers, regulators and members of congress. All people trying to make a difference in the treatment and care of patients with kidney disease. We feel very fortunate to get a chance to talk about the future we're building for those patients at Trestle Biotherapeutics, and are always honored by the support of these groups and others such as National Kidney Foundation and American Society of Nephrology.
关于我们
Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered therapies for patients living with end stage renal disease. Once implanted, these bioengineered stem cell-derived tissues will get patients off dialysis, delay their need for transplantation, and one day become replacement organs.
- 网站
-
https://www.trestlebio.com
Trestle Biotherapeutics的外部链接
- 所属行业
- 生物技术
- 规模
- 2-10 人
- 类型
- 私人持股
Trestle Biotherapeutics员工
动态
-
Last week, our Co-founder and CEO Ben Shepherd, spent time in Manchester, NH with Advanced Regenerative Manufacturing Institute (ARMI) | BioFabUSA and talked kidney innovation and progress with an incredible panel, including 3-time transplant recipient and cancer survivor VANESSA UNDERWOOD, Kevin Longino of the National Kidney Foundation, and Miromatrix CEO, Jeff Ross, Ph.D. A great opportunity to hear from ESRD and transplant patients, their families, and the organizations and companies building the future of care with them.
-